Forbion Capital Partners
Forbion is a Europe-based venture capital firm focused on building and financing life sciences and bioeconomy companies. The firm combines investment capital with drug-development and company-building expertise, operates multiple fund platforms (Ventures, Growth Opportunities, BioEconomy) and is a signatory to the UN Principles for Responsible Investment. Source content indicates Forbion manages €5bn and has an established track record in life-sciences investing across multiple funds.
Forbion Capital Partners
Naarden, Noord-Holland, The Netherlands, Europe
Services
Equity and growth capital
Provides equity financing across a range of funds and strategies, including seed and company-formation capital, Series A-B for Ventures, later-stage growth capital and cross-over financings in the Growth Opportunities fund, and Series A-B for BioEconomy companies.
Company formation, building and operational support
Assists with company formation (NewCos), company building and operational execution including drug development support, finance, legal and operations functions.
Strategic guidance and sector expertise
Provides strategic guidance leveraging sector experts, scientists and a network of senior advisors to support clinical and commercial development decisions.
Proprietary deal sourcing and corporate access
Proactive deal sourcing and a large industry network, including relationships with big pharma and biotech, used to identify investment and divestment opportunities.
SPAC / public listing support (FEAC)
Through Forbion European Acquisition Corp. (FEAC), offers a vehicle integrated into the Growth Fund to pursue business combinations and facilitate public-market transactions.
Equity and growth capital
Provides equity financing across a range of funds and strategies, including seed and company-formation capital, Series A-B for Ventures, later-stage growth capital and cross-over financings in the Growth Opportunities fund, and Series A-B for BioEconomy companies.
Company formation, building and operational support
Assists with company formation (NewCos), company building and operational execution including drug development support, finance, legal and operations functions.
Strategic guidance and sector expertise
Provides strategic guidance leveraging sector experts, scientists and a network of senior advisors to support clinical and commercial development decisions.
Proprietary deal sourcing and corporate access
Proactive deal sourcing and a large industry network, including relationships with big pharma and biotech, used to identify investment and divestment opportunities.
SPAC / public listing support (FEAC)
Through Forbion European Acquisition Corp. (FEAC), offers a vehicle integrated into the Growth Fund to pursue business combinations and facilitate public-market transactions.
Portfolio
Two proprietary AAV-based large gene delivery platforms (dual hybrid and AAV intein).
#Gene therapy / AAV-based gene delivery
Focus on vectorized antibodies for CNS diseases.
#Integrated gene therapy (vectorized antibodies for CNS)
Targets cancers dependent on synthetic lethality mechanisms.
#Oncology / synthetic lethality approaches
Develops plant-based products with fibrous texture.
#Sustainable food technology / plant-based foods
Develops biologics to modulate cytokine function for cancer patients.
#Biopharmaceuticals / biologics
Develops first-in-class immuno-modulatory antibodies for cancer.
#Immuno-oncology / antibody therapeutics
Two proprietary AAV-based large gene delivery platforms (dual hybrid and AAV intein).
#Gene therapy / AAV-based gene delivery
Focus on vectorized antibodies for CNS diseases.
#Integrated gene therapy (vectorized antibodies for CNS)
Targets cancers dependent on synthetic lethality mechanisms.
#Oncology / synthetic lethality approaches
Develops plant-based products with fibrous texture.
#Sustainable food technology / plant-based foods
Develops biologics to modulate cytokine function for cancer patients.
#Biopharmaceuticals / biologics
Develops first-in-class immuno-modulatory antibodies for cancer.
#Immuno-oncology / antibody therapeutics